Company news

Creative Medical Technology Holdings, Inc. news in 2025

Creative Medical Technology Holdings, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point

December 17, 2025

Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201

December 2, 2025

Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

October 30, 2025

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

October 29, 2025

Creative Medical Technology Holdings Issues Letter to Shareholders

October 27, 2025

Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

October 7, 2025

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain

August 13, 2025

Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

July 17, 2025

Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling

July 11, 2025

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

March 20, 2025

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

March 6, 2025

Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential

February 20, 2025

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

February 13, 2025

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program

February 10, 2025

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

February 4, 2025

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

January 29, 2025